Navigation Links
US study shows that tofacitinib is an efficacious treatment for active RA
Date:5/25/2011

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent improvement in symptoms) when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

Most adverse events were mild and no new safety signals were reported, according to study authors.

Results of the 12 month multinational study, conducted with 792 patients also show that 36.6% and 16.2% of patients achieved ACR50 and ACR70 responses respectively in the 10mg BID group, a significant improvement in symptoms compared to placebo, where 31.2%, 12.7% and 3.2% of patients achieved ACR 20, 50 and 70 respectively. Significant improvements in the Disease Activity Score physician index (DAS28***) were also observed in the treatment groups compared to placebo, along with improvements in the Health Assessment Questionnaire**** (HAQ) compared to placebo.

"We know that JAK plays a fundamental role in the signalling pathways that regulate RA and interrupting the uncontrolled inflammatory cascades seen in this study provides a novel way of modifying the progression of the disease said Professor Joel Kremer of the Albany Medical College in Albany USA. "Tofacitinib appears to reduce the signs and symptoms of RA very rapidly, and we hope that after carefully considering the benefit/risk equation that this compound will provide an additional valuable treatment option for patients who have experienced an inadequate response to prior treatments."

According to researchers, significant ACR 20, ACR50 and ACR70 responses were seen after 2 weeks of therapy (results not published). Patients received concurrent non-biologic background therapy with DMARDs (including methotrexate, leflunomide, sulfasalazine
'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study finds much different work histories for disability rejects, beneficiaries
2. Study Ties Blood Markers to Death Risk in Heart Failure
3. Temple-led study finds widening gap between distracted driving and legislation
4. Brisk walking may help men with prostate cancer, UCSF study finds
5. New study aims to improve long-term treatment for patients with bipolar disorder
6. Medicare improved Canadian doctors salaries: Queens University study
7. IUPUI study first to look at early treatment of depression to reduce heart disease risk
8. A Cultured Man Is a Healthier, Happier Man: Study
9. New study finds that violence doesnt add to childrens enjoyment of TV shows, movies
10. UTMB researcher receives $3 million NIH grant to study aging in Mexico
11. Study finds patient navigation increases colorectal cancer screening in ethnically diverse patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... AB (PRWEB) July 23, 2014 ... of in-home care for seniors, is proud to announce ... Series featuring experts in a wide range of health ... clinical social worker and award-winning author Nancy Kriseman, and ... and ways to prevent burnout by becoming more self-aware. ...
(Date:7/23/2014)... News) -- Regularly checking the pulse of a stroke ... "Screening pulse is the method of choice for checking ... have never had a stroke. Our study shows it ... to identify people who might need more thorough monitoring ... Bernd Kallmunzer, of Erlangen University in Germany. ...
(Date:7/23/2014)... The National Institute of Biomedical Imaging and Bioengineering ... Symposium on July 30, 2014 on the NIH campus. ... investigators covering a wide breadth of NIBIB-funded research. ... Cohen, Harvard, Engineering Microbial Rhodopsins as Optical Voltage Sensor, ... Fluorescently Labeled Probes for Nerve Imaging ...
(Date:7/23/2014)... Angeles, CA (PRWEB) July 23, 2014 ... practices delivering Enhanced External Counterpulsation (EECP), is ... who receives EECP therapy at the health center. ... ischemic heart disease. Since receiving ongoing EECP therapy since ... , When Sara Soulati, CEO of Global Cardio Care, ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a genetic ... behaviors on the autistic spectrum, as well as cognitive ... mental impairment and the most common cause of autism. ... Riverside have published a study that sheds ... Appearing online today (July 23) in the Journal ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... ATLANTA , March 17 Stonebranch, the industry ... businesses and Job Scheduling technology , announced today ... Safe Harbor: What the HITECH Act Means for U.S. Healthcare ... recent healthcare regulations and how healthcare organizations (HCOs), related covered ...
... rate is higher with metal staples, review finds , ... common when orthopedic surgeons use metal staples instead of ... , Infections after surgery can lead to longer hospital ... hip replacement. Infected wounds can also cause serious complications. ...
... March 17 Anatomist and Inventor of Plastination, Dr. ... present their new exhibition, BODY WORLDS of ... premiering at the Neunkirchen Zoo in Germany , beginning ... menagerie, the display features the most revered species in the animal ...
... ... extend to visualize all network communications in the enterprise and those extending out to ... ... of a major update to its Versiera Infrastructure Management System, including new groundbreaking technology ...
... ... Health Makeover Contest and announces that they are increasing the amount of smile makeover winners ... ... nation’s foremost voice in unbiased, expert advice on how to care for your smile and ...
... ... Strategic Leadership Development program for its current and potential physician leaders, through New York ... ... participating in a Strategic Leadership Development program for its current and potential physician leaders. ...
Cached Medicine News:Health News:Stonebranch Publishes Healthcare IT White Paper 2Health News:Stonebranch Publishes Healthcare IT White Paper 3Health News:Stonebranch Publishes Healthcare IT White Paper 4Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 2Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 3Health News:Versiera Enables Cloud and Enterprise Network Visualization 2Health News:Versiera Enables Cloud and Enterprise Network Visualization 3Health News:Dear Doctor Magazine Reveals Makeover Contest Winner's Results and Expands Contest to Include Additional Winners 2Health News:Dear Doctor Magazine Reveals Makeover Contest Winner's Results and Expands Contest to Include Additional Winners 3Health News:Summit Medical Group Prepares Physicians for Future Leadership 2
(Date:7/23/2014)... 2014 Announced at the 20 th ... agreement seeks to increase access to a promising new HIV ... 2014 conference in Melbourne today, the ... Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine ... in India and China ...
(Date:7/23/2014)... 2014 Today,s U.S. Food and Drug ... with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma ... significant advance for patients with these blood cancers.  ... trade name Zydelig®, is a first-in-class inhibitor of ... in many B-cell malignancies and plays a critical ...
(Date:7/23/2014)... ALTO, Calif., July 23, 2014  Varian Medical Systems ... earnings of $1.02 per diluted share in the third ... impacted by about $0.06 per diluted share due to ... portion of Varian,s existing equity investment in Augmenix, a ... company-wide revenues totaled $748 million for the third quarter ...
Breaking Medicine Technology:The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10
... 9, 2010 Alere Inc. (NYSE: ALR ), ... their health at home through the merger of rapid diagnostics ... Lazard Capital Markets 7th Annual Healthcare Conference being held November ...  Jon Russell, Vice President, Finance, will attend.  Mr. Russell,s presentation ...
... Across the country, thousands of senior citizens and people living ... well enough in their homes to groom themselves, prepare meals ... are often difficult for those in need of mobility assistance, ... For Medicare beneficiaries in need of mobility assistance, the lame-duck ...
Cached Medicine Technology:Congress Urged to Delay New Medicare Wheelchair Rental Policy 2Congress Urged to Delay New Medicare Wheelchair Rental Policy 3Congress Urged to Delay New Medicare Wheelchair Rental Policy 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: